ERBB2 and gastric cancer: Clinical trials evaluating trastuzumab, a monoclonal antibody targeting HER2, when combined with chemotherapy in patients with HER2-positive breast and gastric cancers yielded objective response rates (ORR) of ~50% and median overall survivals (mOS) surpassing 1–2 years (4, 5).